http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Nov 2025 07:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/Bernstein+explains+why+this+big+pharma+stock+%27should+continue+to+work%27/25574742.html <p>Bernstein have raised their price target for this British pharmaceutical company, to £22.50 from £21.70, arguing its shares should continue delivering strong performance into 2026 despite already climbing 31.2% year-to-date through November 3.</p><p>The brokerage maintained an “outperform” rating on GSK Plc, which closed at £17.57 on November 3, according to analysts Justin Smith and Florent Cespedes from Bernstein.</p><p>The stock has outperformed the Bloomberg Europe Developed Markets Large & Mid Cap Price Return Index by 6.4% year-to-date and trades with a market capitalization of £71,749 million and a dividend yield of 3.6%.</p><p>"Whilst the shares have performed strongly since 29/9/25 (due to http://www.streetinsider.com/Hot+List/Bernstein+explains+why+this+big+pharma+stock+%27should+continue+to+work%27/25574742.html Fri, 07 Nov 2025 07:00:00 -0500 GLAXF http://www.streetinsider.com/Hot+List+Pro/Bernstein+explains+why+this+big+pharma+stock+%27should+continue+to+work%27/25574742.html <p>Bernstein have raised their price target for this British pharmaceutical company, to £22.50 from £21.70, arguing its shares should continue delivering strong performance into 2026 despite already climbing 31.2% year-to-date through November 3.</p><p>The brokerage maintained an “outperform” rating on GSK Plc, which closed at £17.57 on November 3, according to analysts Justin Smith and Florent Cespedes from Bernstein.</p><p>The stock has outperformed the Bloomberg Europe Developed Markets Large & Mid Cap Price Return Index by 6.4% year-to-date and trades with a market capitalization of £71,749 million and a dividend yield of 3.6%.</p><p>"Whilst the shares have performed strongly since 29/9/25 (due to http://www.streetinsider.com/Hot+List+Pro/Bernstein+explains+why+this+big+pharma+stock+%27should+continue+to+work%27/25574742.html Fri, 07 Nov 2025 07:00:00 -0500 GLAXF http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0500 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Hot+List/GSK+shares+slide+as+US+CDC+limits+RSV+vaccine+scope%3B+analysts+weigh+in/23403670.html <p>Shares in GSK fell more than 6% on Thursday after the U.S. Centers for Disease Control and Prevention (CDC) narrowed its usage recommendation for respiratory syncytial virus (RSV) vaccines. </p><p>The CDC now advises the vaccine for individuals aged 60 to 74 who are at increased risk of severe RSV due to medical conditions but refrained from recommending it for those under 60.</p><p>This decision is a setback for GSK, which manufactures the Arexvy RSV vaccine and had high hopes for it to become a blockbuster product. The company is facing patent expiries and declining revenues from its current top-selling drugs by http://www.streetinsider.com/Hot+List/GSK+shares+slide+as+US+CDC+limits+RSV+vaccine+scope%3B+analysts+weigh+in/23403670.html Thu, 27 Jun 2024 04:59:18 -0500 GLAXF http://www.streetinsider.com/Momentum+Movers/GSK+shares+slide+as+US+CDC+limits+RSV+vaccine+scope%3B+analysts+weigh+in/23403670.html <p>Shares in GSK fell more than 6% on Thursday after the U.S. Centers for Disease Control and Prevention (CDC) narrowed its usage recommendation for respiratory syncytial virus (RSV) vaccines. </p><p>The CDC now advises the vaccine for individuals aged 60 to 74 who are at increased risk of severe RSV due to medical conditions but refrained from recommending it for those under 60.</p><p>This decision is a setback for GSK, which manufactures the Arexvy RSV vaccine and had high hopes for it to become a blockbuster product. The company is facing patent expiries and declining revenues from its current top-selling drugs by http://www.streetinsider.com/Momentum+Movers/GSK+shares+slide+as+US+CDC+limits+RSV+vaccine+scope%3B+analysts+weigh+in/23403670.html Thu, 27 Jun 2024 04:59:18 -0500 GLAXF http://www.streetinsider.com/Hot+List/GSK+shares+tumble+9%25+after+70%2C000+Zantac+lawsuits+allowed+to+move+forward/23309703.html <p>Shares in British drugmaker GSK fell sharply Monday following a Delaware judge's decision to allow more than 70,000 lawsuits to proceed, alleging that its discontinued heartburn medication Zantac caused cancer.</p><p>The stock plunged more than 9.1% in London trading.</p><p>GSK expressed its disagreement with the ruling and announced plans to appeal immediately.</p><p>J.P. Morgan analysts indicated that GSK's potential liability from the litigation could exceed the $2 billion to $3 billion that the market had anticipated.</p><p>The judge's decision, issued late Friday, permits expert witnesses to testify that Zantac may cause cancer. GSK, along with former Zantac manufacturers Pfizer, Sanofi, and Boehringer Ingelheim, had http://www.streetinsider.com/Hot+List/GSK+shares+tumble+9%25+after+70%2C000+Zantac+lawsuits+allowed+to+move+forward/23309703.html Mon, 03 Jun 2024 06:08:08 -0500 GLAXF GSK SNY http://www.streetinsider.com/Hot+List/GSK+shares+tumble+9%25+after+70%2C000+Zantac+lawsuits+allowed+to+move+forward/23309703.html <p>Shares in British drugmaker GSK fell sharply Monday following a Delaware judge's decision to allow more than 70,000 lawsuits to proceed, alleging that its discontinued heartburn medication Zantac caused cancer.</p><p>The stock plunged more than 9.1% in London trading.</p><p>GSK expressed its disagreement with the ruling and announced plans to appeal immediately.</p><p>J.P. Morgan analysts indicated that GSK's potential liability from the litigation could exceed the $2 billion to $3 billion that the market had anticipated.</p><p>The judge's decision, issued late Friday, permits expert witnesses to testify that Zantac may cause cancer. GSK, along with former Zantac manufacturers Pfizer, Sanofi, and Boehringer Ingelheim, had http://www.streetinsider.com/Hot+List/GSK+shares+tumble+9%25+after+70%2C000+Zantac+lawsuits+allowed+to+move+forward/23309703.html Mon, 03 Jun 2024 06:08:08 -0500 GLAXF GSK SNY http://www.streetinsider.com/Hot+List/GSK+shares+tumble+9%25+after+70%2C000+Zantac+lawsuits+allowed+to+move+forward/23309703.html <p>Shares in British drugmaker GSK fell sharply Monday following a Delaware judge's decision to allow more than 70,000 lawsuits to proceed, alleging that its discontinued heartburn medication Zantac caused cancer.</p><p>The stock plunged more than 9.1% in London trading.</p><p>GSK expressed its disagreement with the ruling and announced plans to appeal immediately.</p><p>J.P. Morgan analysts indicated that GSK's potential liability from the litigation could exceed the $2 billion to $3 billion that the market had anticipated.</p><p>The judge's decision, issued late Friday, permits expert witnesses to testify that Zantac may cause cancer. GSK, along with former Zantac manufacturers Pfizer, Sanofi, and Boehringer Ingelheim, had http://www.streetinsider.com/Hot+List/GSK+shares+tumble+9%25+after+70%2C000+Zantac+lawsuits+allowed+to+move+forward/23309703.html Mon, 03 Jun 2024 06:08:08 -0500 GLAXF GSK SNY